As of Apr. 8 01:55 P.M., Celltrion increased 1.56 percent, compared with yesterday, to 195,000 won. It had declined 5.34 percent through the past month.
Compared with its close competitors within the same industry, KOSPI, even though the investment return of Celltrion was satisfactory among its peer group, its volatility for 1 month was the highest among its peer group.
Comparing industry to the market, the KOSPI industry including Celltrion records lower volatility but a higher earning rate than Medical Supplies. In other words, the industry had been safer with high returns.
Target price 230,000 won
Per analysts’ expectations during the recent month, the average target price of Celltrion is 230,000 won. The stock price is 195,000 won as of yesterday, so there is 35,000 won (17 percent) disparate in order to be able to increase.
While Institutions have been buying Celltrion during the past seven trading day, Foreigners have been selling during the past three trading day.
As a shareholding sum by the investor group for the past four weeks, Institutions have bought 56,620 shares as they turn toward a buying stance and Individuals have bought 484,422 shares with an increasing position. However, during the same period, Foreigners have sold 642,646 shares with the maintenance of a selling position.
Regarding the statistics for the past month on trade volume as the total outstanding shares, the daily turnover rate of Celltrion was 0.4 percent. And the daily volatility, the average range of rise and fall, during the same period is 1.95 percent.
As per the inquiry for shareholding by the investor group, the major investor group is Individuals with 61.06 percent from total outstanding shares. Foreigners and Institutions each hold 18.74 percent and 18.25 percent.
And as recent five-day shareholding change by the investor group, Individuals is the major investor group with 63.8 percent. Institutions hold 21.1 percent and Foreigners hold 14.04 percent.
This article is provided by ThinkPool, a Korean artificial intelligence developer. Its AI algorithm automatically produced this article, which is edited with Google Grammarly. If there are any issues or if readers have any comments, please contact firstname.lastname@example.org or 82-2-6956-6698.